We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Single-Cell Analysis Provides New Insights into Mitochondrial Diseases

By LabMedica International staff writers
Posted on 24 Aug 2020
Print article
Image: The compact Chromium Controller advanced microfluidics platform enables high-throughput analysis. Each single use chip processes up to eight samples in parallel in less than 20 minutes. (Photo courtesy of 10×Genomics).
Image: The compact Chromium Controller advanced microfluidics platform enables high-throughput analysis. Each single use chip processes up to eight samples in parallel in less than 20 minutes. (Photo courtesy of 10×Genomics).
Mitochondrial diseases result from failure of mitochondria, specialized compartments within cells that contain their own DNA and produce the energy needed to sustain life. Some of the most challenging mitochondrial disorders arise from mutations in mitochondrial DNA (mtDNA), a high-copy-number genome that is maternally inherited.

These diseases manifest with marked clinical heterogeneity, in part because tissues generally contain a mixture of both non-mutant and mutant mtDNA, a phenomenon called heteroplasmy. Heteroplasmy varies dramatically across family members, tissues, and time and is hypothesized to be shaped by a combination of random drift and selection.

Medical scientists at the Massachusetts General Hospital (MGH, Boston, MA, USA) and their colleagues applied a single-cell genomics technology, mtDNA single-cell assay for transposase-accessible chromatin (ATAC) sequencing, to determine mtDNA heteroplasmy and cell type simultaneously in many thousands of peripheral-blood mononuclear cells (PBMCs) that were obtained from unrelated patients with Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). The team examined mtDNA within different blood cell types from nine individuals with MELAS, one of the most common forms of mtDNA disease associated with brain dysfunction and stroke-like episodes, with a wide range of severity across patients.

The team obtained samples of venous blood at clinical baseline and purified PBMCs from the patients. They stained cells for viability and applied antihuman CD45 antibodies before fixation and performed fluorescence-activated cell sorting (FACS) to exclude dead and non-leukocyte cells (CD45−). The mtDNA single-cell ATAC sequencing libraries were generated by a 10× Chromium Controller and a modified Chromium Single Cell ATAC Library and Gel Bead Kit protocol (10×Genomics, Pleasanton, CA, USA), which was followed by paired-end sequencing with the use of a NextSeq 500 platform (2× 72-bp reads) (Illumina, San Diego, CA, USA).

By using mtDNA single-cell ATAC sequencing, the team generated high-quality sequencing libraries to simultaneously evaluate cell type and heteroplasmy in thousands of individual cells per patient. Using accessible chromatin signatures derived from nuclear genomic reads, they defined cell states using a latent semantic indexing projection of each patient’s data set onto a single-cell reference map of healthy-donor PBMCs that had been generated by a similar single-cell ATAC sequencing protocol. The analysis revealed especially low levels of heteroplasmy in T cells, which play important roles in killing infected cells, activating other immune cells, and regulating immune responses. They also observed this pattern in six additional patients who had heteroplasmic A3243G without stroke-like episodes.

Melissa A. Walker, MD, PhD, a Pediatric Neurologist and senior author of the study, said, “What makes this study unique is that it is, to our knowledge, the first time anyone has been able to quantify the percentage of disease-causing mitochondrial DNA mutations in thousands of individual cells of different types from the same patient, as well as in multiple patients with inherited mitochondrial disease.” The study was published on August 12, 2020 in the New England Journal of Medicine.





Print article

Channels

Immunology

view channel
Image: An enzyme-linked immunosorbent assay for mannose-binding lectin found that this molecule is associated with coagulopathy in severe COVID-19 patients (Photo courtesy of Getty Images).

Mannose-Binding Lectin Associated with Coagulopathy in Severe COVID-19

The ongoing COVID-19 pandemic has caused significant morbidity and mortality worldwide, as well as profound effects on society. COVID-19 patients have an increased risk of thromboembolic (TE) complications,... Read more

Industry News

view channel
Illustration

2020 AACC Annual Scientific Meeting & Clinical Lab Expo to Be an All Virtual Event Due to Coronavirus Pandemic

The American Association for Clinical Chemistry (AACC Washington, DC, USA) has decided to hold the 2020 AACC Annual Scientific Meeting & Clinical Lab Expo as a virtual event, rather than as a live... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.